Table 1.
Northern California Breast Cancer Family Registry: Characteristics of Women Diagnosed with Hormone Receptor-Positive Breast Cancer, January 1995–September 1998 (Phase I) (n=731)
| Asian American 131 (17.9) n (%)a | Hispanic 96 (13.1) n (%)a | African American 79 (10.8) n (%)a | Non-Hispanic white 425 (58.1) n (%)a | p value | Nonuse of adjuvant hormonal therapy 253 (34.6) n (%)a | Use of adjuvant hormonal therapy 478 (65.4) n (%)a | p value | |
|---|---|---|---|---|---|---|---|---|
| Background characteristics | ||||||||
| Age at diagnosis (mean±SD) | 47.6±9.6 | 49.4±9.5 | 49.4±10.4 | 50.1±10.2 | 0.102 | 46.6±10.4 | 51.0±9.5 | <0.001 |
| Year of diagnosis | ||||||||
| 1995 | 23 (17.6) | 6 (6.3) | 2 (2.5) | 54 (12.7) | <0.001 | 39 (15.4) | 46 (9.6) | 0.129 |
| 1996 | 34 (25.9) | 20 (20.8) | 16 (20.3) | 212 (49.9) | 96 (37.9) | 186 (38.9) | ||
| 1997 | 49 (37.4) | 45 (46.9) | 39 (49.4) | 142 (33.4) | 88 (34.8) | 187 (39.1) | ||
| 1998 | 25 (19.1) | 25 (26.0) | 22 (27.8) | 17 (4.0) | 30 (11.9) | 59 (12.4) | ||
| Marital status | ||||||||
| Single, widowed, separated, or divorced | 33 (25.2) | 36 (37.5) | 39 (49.4) | 144 (33.9) | 0.004 | 87 (34.4) | 165 (34.5) | 0.972 |
| Married or living with partner | 98 (74.8) | 60 (62.5) | 40 (50.6) | 281 (66.1) | 166 (65.6) | 313 (65.5) | ||
| Education level | ||||||||
| College or higher | 71 (54.2) | 21 (21.9) | 20 (25.3) | 195 (45.9) | <0.001 | 99 (39.1) | 208 (43.5) | 0.279 |
| High school diploma or equivalent | 53 (40.5) | 36 (37.5) | 53 (67.1) | 216 (50.8) | 134 (53.0) | 224 (46.9) | ||
| Less than high school | 7 (5.3) | 39 (40.6) | 6 (7.6) | 14 (3.3) | 20 (7.9) | 46 (9.6) | ||
| Health-related indicators and tumor characteristics | ||||||||
| BMI, kg/m2 (mean±SD)b | 23.2±4.2 | 27.0±5.4 | 28.9±6.0 | 25.0±5.3 | <0.001 | 24.7±5.2 | 25.8±5.6 | 0.010 |
| Obese (BMI ≥30 kg/m2) | 7 (5.4) | 25 (26.0) | 28 (35.9) | 73 (17.4) | <0.001 | 36 (14.5) | 97 (20.5) | 0.048 |
| ≥1 indicator of increased genetic susceptibility | 61 (46.6) | 52 (54.2) | 45 (57.0) | 342 (80.5) | <0.001 | 179 (70.8) | 321 (67.2) | 0.320 |
| Positive for BRCA1 or BRCA2 mutationc | 7 (6.1) | 5 (5.3) | 4 (5.5) | 22 (5.4) | 0.993 | 10 (4.2) | 28 (6.2) | 0.270 |
| SEER summary stage | ||||||||
| Localized | 84 (64.1) | 62 (64.6) | 45 (57.0) | 286 (67.3) | 0.064 | 189 (74.7) | 288 (60.2) | <0.001 |
| Regional, direct extension or LN only | 42 (32.1) | 28 (29.2) | 26 (32.9) | 128 (30.1) | 54 (21.3) | 170 (35.6) | ||
| Regional, direct extension+LN | 5 (3.8) | 6 (6.2) | 8 (10.1) | 11 (2.6) | 10 (4.0) | 20 (4.2) | ||
| Histologic typed | ||||||||
| Ductal | 107 (81.7) | 77 (80.2) | 57 (75.0) | 331 (79.2) | 0.28 | 196 (78.7) | 376 (79.7) | 0.001 |
| Lobular/mixed lobular | 17 (13.0) | 14 (14.6) | 8 (10.5) | 57 (13.6) | 24 (9.6) | 72 (15.2) | ||
| Other specified histology | 7 (5.3) | 5 (5.2) | 11 (14.5) | 30 (7.2) | 29 (11.7) | 24 (5.1) | ||
| Treatment for breast cancer | ||||||||
| Surgery and radiatione | ||||||||
| Mastectomy±radiation | 73 (57.0) | 44 (46.3) | 32 (41.6) | 204 (48.6) | 0.132 | 102 (41.3) | 251 (53.1) | <0.001 |
| Lumpectomy+radiation | 50 (39.1) | 49 (51.6) | 44 (57.1) | 210 (50.0) | 133 (53.8) | 220 (46.5) | ||
| Lumpectomy, no radiation | 5 (3.9) | 2 (2.1) | 1 (1.3) | 6 (1.4) | 12 (4.9) | 2 (0.4) | ||
| Chemotherapy | 87 (66.4) | 61 (63.5) | 48 (60.8) | 219 (51.5) | 0.007 | 133 (52.6) | 282 (59.0) | 0.095 |
a
Percents based on nonmissing values.
b
1.0% missing.
c
5.5% missing.
d
1.4% missing.
e
1.5% missing.
BMI, body mass index; LN, lymph node; SD, standard deviation; SEER, Surveillance, Epidemiology and End Results program.